stoxline Quote Chart Rank Option Currency Glossary
  
Beyond Air, Inc. (XAIR)
1.24  -0.07 (-5.34%)    06-21 16:00
Open: 1.3
High: 1.368
Volume: 599,506
  
Pre. Close: 1.31
Low: 1.24
Market Cap: 57(M)
Technical analysis
2024-06-21 4:56:18 PM
Short term     
Mid term     
Targets 6-month :  1.65 1-year :  1.93
Resists First :  1.41 Second :  1.65
Pivot price 1.23
Supports First :  1.19 Second :  1.05
MAs MA(5) :  1.27 MA(20) :  1.22
MA(100) :  1.49 MA(250) :  2.12
MACD MACD :  0 Signal :  -0.1
%K %D K(14,3) :  63.9 D(3) :  70.2
RSI RSI(14): 49.3
52-week High :  4.83 Low :  1.05
Price, MAs and Bollinger Bands

Price has closed below its short-term moving average. Short-term moving average is currently above mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and NEUTRAL in mid-long term.
[ XAIR ] has closed below upper band by 49.6%. Bollinger Bands are 60.8% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 9 bars. This is a sign that the market may be about to initiate a new trend.

Stock Price Prediction
If tomorrow: Open lower Open higher
High: 1.37 - 1.38 1.38 - 1.38
Low: 1.23 - 1.23 1.23 - 1.24
Close: 1.23 - 1.24 1.24 - 1.25
Company Description

Beyond Air, Inc. operates as a commercial medical device and biopharmaceutical company. The company engages in the development of LungFit platform, a nitric oxide generator and delivery system. It offers LungFit PH for the treatment of persistent pulmonary hypertension of the newborn. The company is also developing LungFit PRO for the treatment of viral lung infections, such as community-acquired viral pneumonia, including COVID-19, as well as bronchiolitis in hospitalized patients; and LungFit GO for the treatment of nontuberculous mycobacteria. The company was formerly known as AIT Therapeutics, Inc. and changed its name to Beyond Air, Inc. in June 2019. Beyond Air, Inc. is based in Garden City, New York.

Headline News

Fri, 14 Jun 2024
Beyond Air Appoints David Webster as Chief Commercial Officer - citybiz

Thu, 13 Jun 2024
Beyond Air® Appoints David Webster as Chief Commercial Officer - StockTitan

Tue, 30 Apr 2024
Bullish Beyond Air Insider Buying Worth US$3.05m Yet To Pay Off - Simply Wall St

Sun, 28 Apr 2024
Beyond Air, Inc.'s (NASDAQ:XAIR) Profit Outlook - Yahoo Movies UK

Thu, 21 Mar 2024
Beyond Air (XAIR) Upgraded to Buy: What Does It Mean for the Stock? - Yahoo Finance

Tue, 13 Feb 2024
Beyond Air, Inc. (XAIR) Q3 2024 Earnings Call Transcript - Seeking Alpha

Financial Analysis
Price to Book Value:
P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.
Outperform
Price to Earnings:
PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).
Outperform
Discounted cash flow:
DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.
Outperform
Return on Assets:
ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.
Underperform
Return on Equity:
ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.
Underperform
Debt to Equity:
evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.
Outperform
Stock Basics & Statistics
Exchange:
NASDAQ
Sector:
Healthcare
Industry:
Medical - Devices
Shares Out 0 (M)
Shares Float 46 (M)
Held by Insiders 2.674e+007 (%)
Held by Institutions 17.9 (%)
Shares Short 3,210 (K)
Shares Short P.Month 0 (K)
Stock Financials
EPS -6.278e+007
EPS Est Next Qtrly 0
EPS Est This Year 0
EPS Est Next Year 0
Book Value (p.s.) 0
Profit Margin 0 %
Operating Margin -4 %
Return on Assets (ttm) 338.3 %
Return on Equity (ttm) -64 %
Qtrly Rev. Growth 689000 %
Gross Profit (p.s.) 0
Sales Per Share -17967
EBITDA (p.s.) 0
Qtrly Earnings Growth -2.2 %
Operating Cash Flow 0 (M)
Levered Free Cash Flow -54 (M)
Stock Valuations
PE Ratio -0.01
PEG Ratio 0
Price to Book value 0
Price to Sales -0.01
Price to Cash Flow 0.02
Stock Dividends
Dividend 0
Forward Dividend 3.78e+006
Dividend Yield 0%
Dividend Pay Date Invalid DateTime.
Ex-Dividend Date Invalid DateTime.

StockChart iOS

StoxlineLite iOS

StoxlineLite iOS

OptionCalc iOS

StockChart Android

StoxlineLite Android

StoxlinePro Android

OptionCalc Android